Skip to main content

Breast Cancer Screening

Breast cancer is the most common malignancy in women worldwide. Randomized trials showed that screening mammography can reduce breast cancer mortality by detecting cancers before clinical presentation.[1][10] NCCN recommends breast cancer risk assessment by age 25, with periodic reassessment. Screening modality, frequency and starting age depend on risk category.[2]

Average-risk screening​

Major guidelines agree that screening mammography reduces breast cancer mortality but differ on when to start, how often to screen, and when to stop. Digital breast tomosynthesis (DBT) is preferred when available. NCCN cites lower callback rates and higher cancer detection than with standard 2D mammography alone.[2]

GuidelineStart ageFrequencyStop / Upper limit
USPSTF (2024)[1]40Biennial through age 74Evidence insufficient to recommend for or against screening at age ≥75
NCCN (2026)[2]40AnnualNo established upper age limit; consider comorbidity, life expectancy and whether treatment would be appropriate and acceptable
ACS[3]45 (option to start at 40)Annual 45–54; biennial or continued annual ≥55Continue with good health and ≥10-year life expectancy
ACR[15]40AnnualContinue beyond 74 unless severe comorbidity limits life expectancy
ACOG (2024 update)[19][20]40Every 1–2 yearsContinue through at least age 75; individualize thereafter
ACP (2026)[5]50 (shared decision-making 40–49)BiennialAge 74; discuss stopping at ≥75 or limited life expectancy

Guideline positions:

  • USPSTF (2024). The task force recommends biennial screening mammography for ages 40–74 (B recommendation). The 2016 version had individualized the decision for ages 40–49. Evidence is insufficient for screening at age 75 or older and for supplemental screening in dense breasts.[1]
  • NCCN (2026). NCCN recommends annual mammography with tomosynthesis starting at age 40 (Category 1). Clinical encounters are advised every 1–3 years for ages 25–39 and annually from age 40. There is no established upper age limit; consider comorbidity, life expectancy and whether treatment after an abnormal finding would be appropriate and acceptable.[2]
  • ACS. Annual mammography is advised for ages 45–54, with the option to begin at 40. From age 55, screening is biennial or continues annually while the patient is in good health with a life expectancy of at least ten years.[3]
  • ACR. ACR advises annual mammography starting at age 40, continuing beyond age 74 unless severe comorbidity limits life expectancy.[15] The cited ACR/SBI statement gives no fixed 5–7-year threshold.[15][4]
  • ACP (2026). ACP guidance is biennial mammography for ages 50–74, a shared decision at ages 40–49 (biennial screening if the patient prefers it), and a discussion of discontinuation at age 75 or older or with limited life expectancy. Supplemental DBT may be considered in BI-RADS C or D density, and supplemental MRI or ultrasound is not advised in average-risk patients with dense breasts.[5]

Increased-risk categories and screening​

Risk assessment should be performed by age 25 and periodically reassessed.[2] NCCN defines several increased-risk categories, each with its own screening protocol.[2][6]

Residual lifetime risk ≥20% (by comprehensive family-history models)​

Annual mammography with tomosynthesis and annual breast MRI with and without contrast. For each modality, begin no later than age 40 or 10 years before the youngest affected family member's diagnosis, whichever comes first, ordinarily no earlier than age 30 for mammography and age 25 for MRI. NCCN allows case-by-case mammography from age 25 based on family history or inability to undergo MRI, and MRI before age 25 in rare families with breast cancers before age 30.[2]

Known genetic predisposition (e.g., BRCA1/2)​

  • Ages 25–29. Annual breast MRI with contrast (mammography only if MRI unavailable).
  • Ages 30–75. Annual mammography with tomosynthesis plus annual breast MRI with contrast.
  • Risk-reducing mastectomy counseling is part of management.[6]

Prior chest radiation (ages 10–30)​

Use a dedicated high-risk pathway that accounts for treatment age and elapsed time. The ACR 2025 criteria specify mammography eight years after young-age thoracic/upper-abdominal radiation, not before age 25, with supplemental MRI according to the risk-based schedule. ACR recommends annual mammography for women exposed to thoracic or upper-abdominal radiation before age 30.[16][2]

5-year invasive breast cancer risk ≥1.7% (Gail at age ≥35 or an imaging-based model); ADH or LCIS/ALH​

For a 5-year invasive breast cancer risk ≥1.7% by Gail at age ≥35 or by an imaging-based risk model, begin annual mammography with tomosynthesis and clinical encounters every 6–12 months when increased risk is identified; consider annual breast MRI with and without contrast. For ADH or LCIS/ALH, start clinical encounters every 6–12 months at diagnosis, begin annual mammography with tomosynthesis at diagnosis but not before age 30, and consider annual breast MRI with and without contrast at diagnosis but not before age 25.[2]

Dense breast tissue (heterogeneously or extremely dense)​

Recommendations differ. ACR supports supplemental contrast MRI for appropriate dense-breast risk categories[16], whereas USPSTF finds evidence insufficient to determine the overall benefit–harm balance[1] and ACP 2026 recommends against supplemental MRI/ultrasound for average-risk dense breasts.[5]

In the DENSE trial, women aged 50–75 with extremely dense breasts and a normal mammogram who were invited to MRI had fewer interval cancers (2.5 vs 5.0 per 1,000 screens; 59% accepted the invitation).[17] The endpoint was interval cancer, not mortality.

Supplemental screening modalities​

Supplemental breast imaging may increase cancer detection in selected patients after assessment of breast density and other risk factors, and may increase recalls and benign breast biopsies.[2][7][8]

ModalityIncremental CDR per 1,000Notes
Breast MRI with contrastDENSE: 16.5 per 1,000 among women screened with MRIHighest incremental CDR of the supplemental modalities in a meta-analysis; interval cancers 2.5 vs 5.0 per 1,000 in DENSE; increases false positives and biopsy rate[7][8][9][10]
Abbreviated breast MRI7.0 additional invasive cancers per 1,000 versus DBT (Comstock)Absolute invasive CDR was 11.8 versus 4.8 per 1,000; for invasive cancer or DCIS, sensitivity was 95.7% versus 39.1% and specificity was 86.7% versus 97.4% (abbreviated MRI versus DBT). Scans are shorter than full-protocol MRI.[2][11]
Contrast-enhanced mammography (CEM)BRAID first round: 19.2 cancers per 1,000 examinations after negative mammographyNCCN considers CEM for high-risk patients who cannot undergo breast MRI. In women aged 50–70 with dense breasts, a randomized comparison found, among participants completing supplemental imaging, 39/2,035 cancers with CEM, 37/2,130 with abbreviated MRI, and 9/2,141 with automated ultrasound. Among 2,035 CEM examinations, there were 24 iodinated-contrast reactions (17 minor, six moderate, one severe) and three extravasations.[2][7][18]
Molecular breast imaging (MBI)Population-dependentNCCN considers MBI for high-risk patients who cannot undergo breast MRI; its whole-body effective radiation dose exceeds that of standard mammography.[2]
Whole-breast ultrasoundLower than MRILower incremental CDR than MRI in the meta-analysis; increases false positives[2][8]

A simulation study estimated the benefits and harms of density-targeted MRI strategies. Adding MRI for women with extremely dense breasts to biennial DBT at ages 50–74 averted 7.6 vs 7.4 breast cancer deaths and produced 919 vs 884 false-positive recalls per 1,000 simulated women.[9]

Risk assessment tools​

Breast cancer risk assessment should be performed by age 25 and reassessed periodically. For comprehensive family-history assessment, NCCN lists BRCAPRO, Tyrer-Cuzick, BOADICEA/CanRisk and the BCSC invasive breast cancer risk calculator.[2][12]

ModelKey inputsBest use case
Tyrer-Cuzick (IBIS)Personal / family history, BRCA probability, mammographic density, hormonal factorsIncludes extended pedigree and reproductive/density factors; no universally best model
BCSCAge, race/ethnicity, family history (1st-degree), prior biopsy, breast densityHighest AUC in the density-available subgroup of the cited cohort[13]
Gail (BCRAT)Age, family history (1st-degree only), prior biopsy, ethnicityWidely used; moderate discrimination in the cited cohort (AUC 0.64). NCCN recommends considering risk-reduction strategies when the 5-year invasive breast cancer risk is ≥1.7% by Gail at age ≥35.[13][2]
BOADICEAPersonal / family history, germline mutation results, tumor pathologyIncludes detailed pedigree and genetic risk; use a version validated for the clinical population

In the 35,921-woman mammography cohort, BRCAPRO, Gail, and Tyrer–Cuzick versions 7 and 8 had AUCs of 0.61–0.64. The BCSC model had the highest AUC among women with available breast density information.[13]

Emerging evidence: risk-based screening​

The WISDOM trial randomized 28,372 participants aged 40–74 with median 5.1-year follow-up. Risk-based screening met noninferiority for the rate of stage ≥IIB cancers (difference −18.0 per 100,000 person-years; 95% CI −40.2 to 4.1), but did not reduce the co-primary biopsy outcome (difference 98.7 per 100,000 person-years; 95% CI −17.9 to 215.3), despite fewer mammograms.[14] Risk-based screening integrated:

  • Genetic testing (9 susceptibility genes plus polygenic risk score)
  • BCSC risk model
  • Four screening tiers: deferred screening (low risk) to alternating mammography / MRI every 6 months (highest risk)

Among 18,031 participants who declined randomization and entered the observational cohort, 89% chose risk-based screening.[14]

Special populations​

  • Age ≥75. Evidence is insufficient to assess benefits and harms of continued screening (USPSTF I statement). NCCN has no established upper age limit and advises considering comorbidity, life expectancy and whether treatment after an abnormal finding would be appropriate and acceptable.[1][2]
  • BRCA carriers (male). Clinical breast examination is advised annually from age 35, and annual mammography can be considered from age 50 (or 10 years before the earliest known male breast cancer in the family), particularly for BRCA2 carriers.[6]
  • Transgender individuals. NCCN endorses ACR Appropriateness Criteria for screening guidance in transgender patients.[2]
  • Racial disparities. Non-Hispanic Black women have 40% higher breast cancer mortality than White women despite lower incidence.[1] Disparities have been documented in time to diagnostic imaging and biopsy after an abnormal screening result.[1][2][10] The Women's Preventive Services Initiative recommends individualized person-to-person navigation for breast screening and follow-up after abnormal results.[21]

See Also​

References​

1. Nicholson WK, Silverstein M, Wong JB, et al. "Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement." JAMA. 2024;331(22):1918–1930. doi:10.1001/jama.2024.5534

2. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis. Version 1.2026. Updated 2026-03-05. https://www.nccn.org

3. American Cancer Society. Breast Cancer Screening Guidelines. Official recommendations

4. Khan M, Chollet A. "Breast Cancer Screening: Common Questions and Answers." Am Fam Physician. 2021;103(1):33–41. PMID 33382554

5. Qaseem A, Harrod CS, Balk EM, et al. "Screening for Breast Cancer in Asymptomatic, Average-Risk Adult Females: A Guidance Statement From the American College of Physicians (Version 2)." Ann Intern Med. 2026. doi:10.7326/ANNALS-25-05116

6. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 1.2027. Updated 2026-08-31. https://www.nccn.org

7. Holt DB. "Breast Density Masking and the Need for Precision Screening." JAMA. 2026. doi:10.1001/jama.2026.2443

8. Hussein H, Abbas E, Keshavarzi S, et al. "Supplemental Breast Cancer Screening in Women With Dense Breasts and Negative Mammography: A Systematic Review and Meta-Analysis." Radiology. 2023;306(3):e221785. doi:10.1148/radiol.221785

9. Stout NK, Miglioretti DL, Su YR, et al. "Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and Magnetic Resonance Imaging by Breast Density." JAMA Intern Med. 2024;184(10):1222–1231. doi:10.1001/jamainternmed.2024.4224

10. Henderson JT, Webber EM, Weyrich MS, Miller M, Melnikow J. "Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force." JAMA. 2024;331(22):1931–1946. doi:10.1001/jama.2023.25844

11. Comstock CE, Gatsonis C, Newstead GM, et al. "Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening." JAMA. 2020;323(8):746–756. doi:10.1001/jama.2020.0572

12. National Comprehensive Cancer Network. Breast Cancer Risk Reduction. Updated 2025-08-29. https://www.nccn.org

13. McCarthy AM, Guan Z, Welch M, et al. "Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort." J Natl Cancer Inst. 2020;112(5):489–497. doi:10.1093/jnci/djz177

14. Esserman LJ, Fiscalini AS, Naeim A, et al. "Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial." JAMA. 2026;335(9):763–774. doi:10.1001/jama.2025.24784

15. ACR/SBI. Statement on New USPSTF Breast Cancer Screening Recommendations. 2023. Official statement.

16. ACR. Appropriateness Criteria: Female Breast Cancer Screening (2025) and Supplemental Breast Cancer Screening Based on Breast Density. Screening criteria; density-specific criteria.

17. Bakker MF, et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med. 2019. doi:10.1056/NEJMoa1903986.

18. Gilbert FJ, Payne NR, Allajbeu I, et al. "Comparison of supplemental breast cancer imaging techniques—interim results from the BRAID randomised controlled trial." Lancet. 2025;405(10493):1935-1944. doi:10.1016/S0140-6736(25)00582-3

19. American College of Obstetricians and Gynecologists. "Age to Initiate Routine Breast Cancer Screening: ACOG Clinical Practice Update." Obstet Gynecol. 2025;145(1):e40–e44. doi:10.1097/AOG.0000000000005757

20. Committee on Practice Bulletins—Gynecology. "Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women." Obstet Gynecol. 2017;130(1):e1–e16. doi:10.1097/AOG.0000000000002158

21. Witkop CT, Picardo C, Vosooney A, et al. "Recommendations From the Women's Preventive Services Initiative on Breast Cancer Screening for Women at Average Risk and Patient Navigation Services for Breast and Cervical Cancer Screening." Obstet Gynecol. 2025;146(3):315–322. doi:10.1097/AOG.0000000000006011

22. Mor-Hadar D, Wilailak S, Berek J, McNally OM; FIGO Committee on Women's Cancer. "FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy." Int J Gynaecol Obstet. 2024;167(3):976–980. doi:10.1002/ijgo.15884